Sepsis News and Research

Latest Sepsis News and Research

Cheetah Medical launches new NICOM System with integrated Pulse Oximetry functionality in Europe

Cheetah Medical today announced the European launch of its new NICOM(R) System which offers an integrated Pulse Oximetry functionality (OxiMax(R) Covidien plc). In addition to core hemodynamic parameters including Cardiac Output (CO), Stroke Volume (SV), Noninvasive Blood Pressure (NIBP), Total Peripheral Resistance (TPR) and Stroke Volume Variation (SVV), the new system provides a new important parameter, Oxygen Delivery Index (DO2I).

15 Oct 2010

FDA approves Gamunex-C for primary immunodeficiency treatment

Talecris Biotherapeutics announced today that the U.S. Food and Drug Administration (FDA) approved Gamunex-C (Immune Globulin Injection [Human], 10% Caprylate/Chromatography Purified) for subcutaneous administration in the treatment of primary immunodeficiency (PI).

15 Oct 2010

Sirius collaborates with Golden Helix to advance diagnostic pipeline

Sirius Genomics, a developer of companion diagnostics, and Golden Helix, a global leader in genetic analysis solutions, announced today a collaboration under which Golden Helix will apply its expertise and technologies in SNP and copy number variant analysis and predictive modeling to advance development of Sirius' diagnostic pipeline.

13 Oct 2010

Allos announces favorable survival data from FOLOTYN Phase 2b study

Allos Therapeutics, Inc. today announced the presentation of favorable survival data from the Company's international, randomized Phase 2b investigational study of FOLOTYN relative to erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC). In this study, patients receiving FOLOTYN had a 16 percent reduction in the risk of death compared to erlotinib in the overall (intent-to-treat) population.

11 Oct 2010

Progenics receives NIH grant to develop novel monoclonal antibodies to treat C. difficile infection

Progenics Pharmaceuticals, Inc. today announced the award of a grant totaling $4,143,652 from the National Institutes of Health (NIH) for Progenics' program to develop novel monoclonal antibodies to treat Clostridium difficile (C. difficile) infection.

7 Oct 2010

Rochester General Hospital Research Institute awarded $7M for Prevnar 13 study of ear infections in children

The Rochester General Hospital Research Institute has been awarded a $7.1 million grant to study the effectiveness of a new vaccine on the bacteria that cause ear infections in children. Michael E. Pichichero MD, Director of the Research Institute, has been named Principal Investigator of the five year study which will follow children who receive the Prevnar 13 vaccine. The vaccine is manufactured by Pfizer Vaccine Research of Collegeville, Pennsylvania which is funding the grant.

6 Oct 2010

Sirius Genomics signs second Contribution Agreement with NRC-IRAP

Sirius Genomics, a developer of companion diagnostics, announced today that it has signed its second Contribution Agreement with the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP).

5 Oct 2010

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.

4 Oct 2010

GSA urges treatment of sepsis as a medical emergency

The Global Sepsis Alliance (GSA) is urging healthcare providers, patients and policymakers worldwide to treat sepsis as a medical emergency. "Tens of millions of people die from sepsis each year, making it the likely leading cause of death worldwide. Sepsis kills regardless of age, ethnicity, location and access to care," said Konrad Reinhart, M.D., Chairman of the GSA and director of the Department of Anesthesiology and Intensive Care Medicine, University Hospital of the Friedrich Schiller, University of Jena, Germany.

1 Oct 2010

National survey shows 60% of U.S. adults not familiar with sepsis

Sixty percent of U.S. adults are not familiar with sepsis, despite the fact that more than 200,000 Americans die from it every year, making sepsis one of the leading causes of death in the nation. Lack of awareness is even higher among adults over age 65, who are at greater risk of sepsis, according to a new national survey sponsored by The Feinstein Institute for Medical Research in Manhasset, NY, part of the North Shore–LIJ Health System.

28 Sep 2010

GBS pathogen suppresses immune cell function in newborn infants: Research

Group B Streptococcus (GBS), a bacterial pathogen that causes sepsis and meningitis in newborn infants, is able to shut down immune cell function in order to promote its own survival, according to researchers at the University of California, San Diego School of Medicine and the Skaggs School of Pharmacy and Pharmaceutical Sciences.

27 Sep 2010

Pollution increases risk for sudden cardiac arrest

The fine particles of pollution that hang in the air can increase the risk for sudden cardiac arrest, according to a new study conducted by a team from Long Island Jewish (LIJ) Medical Center and The Feinstein Institute for Medical Research.

21 Sep 2010

Oxygen Biotherapeutics announces CRADA Agreement amendment

Oxygen Biotherapeutics, Inc. today announced it has amended an existing Cooperative Research and Development Agreement (CRADA) with the U.S. Naval Medical Research Center (NMRC) to include preclinical trials using swine models to assess the safety and efficacy of Oxygen Biotherapeutics' proprietary Oxycyte perfluorocarbon emulsion (PFCE) for spinal cord injury (SCI) due to decompression sickness (DCS), and for hemorrhagic shock.

20 Sep 2010

Novel Compound's NVC-422 broad-spectrum antimicrobial agent kills P. mirabilis bacteria in catheters

Patients fitted with long-term bladder catheters often face a potentially serious complication caused by a Gram-negative bacteria Proteus mirabilis that can colonize the catheters.

16 Sep 2010

Atox Bio doses first subject in AB103 Phase 1 study for severe bacterial infections and sepsis

Atox Bio Inc. today announced that it successfully completed the dosing of the first subject in its phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.

15 Sep 2010

Emergency physicians to present research studies at Research Forum 2010

The risks associated with boarding admitted patients in the emergency department – including patient mortality – as well as proposed solutions will be key themes of Scientific Assembly, the annual meeting of the American College of Emergency Physicians. In addition, emergency physicians will present more than 450 research studies during 2010 Research Forum, the premier, annual scientific research event focused on the latest advances in the practice of emergency medicine.

14 Sep 2010

Progenics Pharmaceuticals presents findings of humanized monoclonal antibodies against C. difficile bacterium

Progenics Pharmaceuticals, Inc. today presented preclinical findings for its humanized monoclonal antibodies against the disease-causing toxins produced by the bacterium Clostridium difficile.

14 Sep 2010

395 new vaccines being developed for infectious diseases: PhRMA

Critical challenges remain in the centuries-old battles against infectious diseases, particularly as bacteria and viruses mutate and as the threat of bioterrorism grows. Responding to this need, America's biopharmaceutical research companies this year have 395 new medicines and vaccines in the pipeline to fight infectious diseases. All 395 are in later stages of development, meaning in clinical trials or under Food and Drug Administration (FDA) review.

10 Sep 2010

Allos Therapeutics to present FOLOTYN trial results at ESMO Congress

Allos Therapeutics, Inc. today announced that results from the Phase 2b investigational trial of FOLOTYN (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) will be presented at the 35th European Society of Medical Oncology (ESMO) Congress

10 Sep 2010

miacom diagnostics presents rapid detection method for pneumonia causing pathogens

miacom diagnostics specializes on the development and production of medical tests for the detection of acute infectious diseases. In addition to its existing sepsis kits miacom, diagnostics is now presenting a further CE-marked product based on the same proprietary technology. It is targeted at the rapid detection of clinically most relevant pneumonia causing pathogens.

7 Sep 2010